Assertio Holdings (ASRT) Total Non-Current Liabilities (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Total Non-Current Liabilities came in at $130.8 million in Q1 2026, down 22.02% year-on-year from $167.8 million in Q1 2025, and down 21.49% quarter-over-quarter from $166.6 million in Q4 2025.
Assertio Holdings (ASRT) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $130.8 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $130.8 million, down 22.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.8 million (down 22.02% YoY), and the FY2025 annual result was $166.6 million, up 8.56% from the prior year.
- Total Non-Current Liabilities came in at $130.8 million for Q1 2026 at Assertio Holdings, down from $166.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $205.9 million in Q3 2025 to a low of $128.9 million in Q3 2024.
- The 5-year median for Total Non-Current Liabilities is $166.6 million (2025), against an average of $160.7 million.
- Across the five-year window, Total Non-Current Liabilities slumped 32.97% in 2023 and surged 59.72% in 2025, its largest moves.
- Assertio Holdings' Total Non-Current Liabilities stood at $183.9 million in 2022, then retreated by 28.25% to $132.0 million in 2023, then rose by 16.33% to $153.5 million in 2024, then advanced by 8.56% to $166.6 million in 2025, then declined by 21.49% to $130.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $130.8 million (Q1 2026), $166.6 million (Q4 2025), and $205.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 130.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.82 Mn |
| Dec 31, 2025 | 166.64 Mn |
| Sep 30, 2025 | 205.95 Mn |
| Jun 30, 2025 | 171.58 Mn |
| Mar 31, 2025 | 167.76 Mn |
| Dec 31, 2024 | 153.50 Mn |
| Sep 30, 2024 | 128.94 Mn |
| Jun 30, 2024 | 130.91 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 131.96 Mn |
| Sep 30, 2023 | 187.16 Mn |
| Jun 30, 2023 | 145.33 Mn |
| Mar 31, 2023 | 137.01 Mn |
| Dec 31, 2022 | 183.92 Mn |
| Sep 30, 2022 | 184.04 Mn |
| Jun 30, 2022 | 170.35 Mn |
| Mar 31, 2022 | 204.41 Mn |
| Dec 31, 2021 | 219.50 Mn |
| Sep 30, 2021 | 171.69 Mn |
| Jun 30, 2021 | 214.47 Mn |